<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890249</url>
  </required_header>
  <id_info>
    <org_study_id>PCOL-102-AHSF</org_study_id>
    <nct_id>NCT04890249</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of Two Tecnis Investigational Lenses</brief_title>
  <official_title>Clinical Investigation of the TECNIS® Intraocular Lens, Models C1V000 and C2V000</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Surgical Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Surgical Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 6-month, prospective, multicenter, randomized (1:1:1), subject-masked and&#xD;
      evaluator-masked, bilateral clinical investigation of the TECNIS IOL Models C1V000 and C2V000&#xD;
      versus the TECNIS Eyhance™ Model ICB00 IOL.&#xD;
&#xD;
      The study will be conducted at up to 15 sites in EU, AU, NZ and/or AP and will enroll up to&#xD;
      225 subjects to achieve approximately 67 bilaterally implanted subjects in each lens group.&#xD;
      Allowing for 10% lost-to-follow-up, this will achieve approximately 60 evaluable subjects in&#xD;
      each lens group at 1, 3, and 6 months. The eye implanted first will be considered the primary&#xD;
      (monocular) study eye.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monocular Photopic distance-corrected intermediate visual acuity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocular Photopic best-corrected distance visual acuity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Cataract</condition>
  <condition>Corneal Astigmatism</condition>
  <arm_group>
    <arm_group_label>Investigational Lens Device #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational IOL Model C1V000</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Lens Device #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational IOL Model C2V000</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control IOL Model ICB00</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Investigational IOL Model C1V000</intervention_name>
    <description>IOL replaces the natural lens removed during cataract surgery.</description>
    <arm_group_label>Investigational Lens Device #1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Investigational IOL Model C2V000</intervention_name>
    <description>IOL replaces the natural lens removed during cataract surgery.</description>
    <arm_group_label>Investigational Lens Device #2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control IOL Model ICB00</intervention_name>
    <description>IOL replaces the natural lens removed during cataract surgery.</description>
    <arm_group_label>Control Lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum 22 years of age&#xD;
&#xD;
          -  Bilateral cataracts or planned natural lens removal (due to immature cataract) for&#xD;
             which phacoemulsification extraction and posterior IOL implantation have been planned&#xD;
             for both eyes&#xD;
&#xD;
          -  Cataractous lens changes, as demonstrated by best-corrected distance visual acuity&#xD;
             (BCDVA) of 0.50 decimal or worse (6/12 or 20/40 Snellen) either with or without a&#xD;
             glare source present (e.g., Brightness Acuity Tester) or with significant&#xD;
             cataract-related visual symptoms in the opinion of the investigator&#xD;
&#xD;
          -  Potential postoperative best-corrected distance visual acuity (BCDVA) of 0.66 decimal&#xD;
             (6/9 or 20/30 Snellen) or better&#xD;
&#xD;
          -  Corneal astigmatism:&#xD;
&#xD;
               -  Normal corneal topography&#xD;
&#xD;
               -  Predicted postoperative corneal astigmatism of less than 1.00 D in both eyes,&#xD;
                  including posterior corneal astigmatism (PCA)&#xD;
&#xD;
          -  Clear intraocular media other than cataract&#xD;
&#xD;
          -  Signed informed consent for participation in the study and data protection&#xD;
&#xD;
          -  Availability, willingness, ability, and sufficient cognitive awareness to comply with&#xD;
             examination procedures and study visits&#xD;
&#xD;
          -  Ability to understand, read, and write English or the local language in which the&#xD;
             informed consent and questionnaires are provided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requiring an intraocular lens power outside the available range of +14.0 D to +26.0 D&#xD;
&#xD;
          -  Any clinically significant pupil abnormalities (non-reactive, fixed pupils, or&#xD;
             abnormally shaped pupils)&#xD;
&#xD;
          -  Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus,&#xD;
             nystagmus, etc.)&#xD;
&#xD;
          -  Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery,&#xD;
             including prophylactic peripheral iridotomies and peripheral laser retinal repairs&#xD;
&#xD;
          -  Corneal abnormalities such as stromal, epithelial, or endothelial dystrophies (e.g.,&#xD;
             any observed guttata) that are predicted to cause visual acuity losses to a level&#xD;
             worse than 0.66 decimal (6/9 or 20/30 Snellen) during the study&#xD;
&#xD;
          -  Irregular corneal astigmatism&#xD;
&#xD;
          -  Inability to achieve keratometric stability for contact lens wearers&#xD;
&#xD;
          -  Recent ocular trauma or ocular surgery that is not resolved/stable or may affect&#xD;
             visual outcomes or increase risk to the subject&#xD;
&#xD;
          -  Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or&#xD;
             other retinal disorders) that are predicted to cause visual acuity losses to a level&#xD;
             worse than 0.66 decimal (6/9 or 20/30 Snellen) during the study&#xD;
&#xD;
          -  Subjects with conditions associated with increased risk of zonular rupture, including&#xD;
             capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as&#xD;
             pseudoexfoliation, trauma, or posterior capsule defects&#xD;
&#xD;
          -  Use of systemic or ocular medications that may affect vision&#xD;
&#xD;
          -  Prior, current, or anticipated use during the course of the 6-month study of&#xD;
             tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of&#xD;
             the investigator, confound the outcome or increase the risk to the subject (e.g., poor&#xD;
             dilation or a lack of adequate iris structure to perform standard cataract surgery)&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
          -  Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the&#xD;
             opinion of the investigator, would increase the operative risk or confound the outcome&#xD;
             of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma,&#xD;
             glaucomatous changes in the fundus or visual field, ocular inflammation, etc.) Note:&#xD;
             Controlled ocular hypertension without glaucomatous changes (optic nerve cupping and&#xD;
             visual field loss) is acceptable&#xD;
&#xD;
          -  Known ocular disease or pathology that, in the opinion of the investigator,&#xD;
&#xD;
               -  may affect visual acuity&#xD;
&#xD;
               -  may require surgical intervention during the course of the study (macular&#xD;
                  degeneration, cystoid macular edema, diabetic retinopathy, uncontrolled glaucoma,&#xD;
                  etc.)&#xD;
&#xD;
               -  may be expected to require retinal laser treatment or other surgical intervention&#xD;
                  during the course of the study (macular degeneration, cystoid macular edema,&#xD;
                  diabetic retinopathy, etc.)&#xD;
&#xD;
          -  Pregnancy, planned pregnancy, presently lactating, or another condition associated&#xD;
             with hormonal fluctuation that could lead to refractive changes&#xD;
&#xD;
          -  Concurrent participation or participation within 60 days prior to preoperative visit&#xD;
             in any other clinical trial&#xD;
&#xD;
          -  Desire for monovision correction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Surgical Vision Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Surgical Vision</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Policastro</last_name>
    <phone>+1 714 7218682</phone>
    <email>apolicas@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vision Eye Institute</name>
      <address>
        <city>Chatswood</city>
        <state>New South Wales</state>
        <zip>2067</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>George St Eye Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunshine Eye Clinic</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queensland Eye Institute</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Eye Ltd</name>
      <address>
        <city>Remuera</city>
        <state>Auckland</state>
        <zip>1050</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Devices Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

